Palmitoylethanolamide (PEA)

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that belongs to the family of endocannabinoids, naturally produced by the body in response to tissue damage and inflammation. Research indicates that PEA supplementation may support the body's natural pain and inflammatory response mechanisms through its interaction with the endocannabinoid system, particularly via PPAR-α receptors and potential enhancement of anandamide signaling.

Clinical studies suggest that PEA may be beneficial for various pain conditions, including neuropathic pain, fibromyalgia, and chronic inflammatory conditions. The compound appears to work by modulating neuroinflammation, reducing mast cell activation, and influencing pain perception pathways. Research indicates that micronized formulations may offer improved bioavailability compared to standard preparations.

While studies suggest PEA has a favorable safety profile with minimal reported side effects, the research base consists primarily of smaller clinical trials and pilot studies. Most trials have used dosages ranging from 300-1200mg daily, with micronized formulations potentially requiring lower doses. As a naturally occurring compound, PEA is generally well-tolerated, though individuals should consult healthcare providers before use, particularly those with existing medical conditions or taking medications.